Chemical genetics reveals an RGS/G-protein role in the action of a compound

被引:30
作者
Fitzgerald, Kevin
Tertyshnikova, Svetlana
Moore, Lisa
Bjerke, Lynn
Burley, Ben
Cao, Jian
Carroll, Pamela
Choy, Robert
Doberstein, Steve
Dubaquie, Yves
Franke, Yvonne
Kopczynski, Jenny
Korswagen, Hendrik
Krystek, Stanley R., Jr.
Lodge, Nicholas J.
Plasterk, Ronald
Starrett, John
Stouch, Terry
Thalody, George
Wayne, Honey
van der Linden, Alexander
Zhang, Yongmei
Walker, Stephen G.
Cockett, Mark
Wardwell-Swanson, Judi
Ross-Macdonald, Petra [1 ]
Kindt, Rachel M.
机构
[1] Bristol Myers Squibb Pharmaceut Res Inst, Pennington, NJ 08534 USA
[2] Exelixis Inc, San Francisco, CA USA
[3] Ctr Biomed Genet, Hubrecht Lab, Utrecht, Netherlands
关键词
D O I
10.1371/journal.pgen.0020057
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We report here on a chemical genetic screen designed to address the mechanism of action of a small molecule. Small molecules that were active in models of urinary incontinence were tested on the nematode Caenorhabditis elegans, and the resulting phenotypes were used as readouts in a genetic screen to identify possible molecular targets. The mutations giving resistance to compound were found to affect members of the RGS protein/G-protein complex. Studies in mammalian systems confirmed that the small molecules inhibit muscarinic G- protein coupled receptor (GPCR) signaling involving G-alpha q (G- protein alpha subunit). Our studies suggest that the small molecules act at the level of the RGS/G-alpha q signaling complex, and define new mutations in both RGS and G-alpha q, including a unique hypo-adapation allele of G-alpha q. These findings suggest that therapeutics targeted to downstream components of GPCR signaling may be effective for treatment of diseases involving inappropriate receptor activation.
引用
收藏
页码:425 / 437
页数:13
相关论文
共 50 条
[1]   New pharmacologic targets for the treatment of the overactive bladder: An update [J].
Andersson, KE .
UROLOGY, 2004, 63 (3A) :32-41
[2]   Sst2 is a GTPase-activating protein for Gpa1:: Purification and characterization of a cognate RGS-Gα protein pair in yeast [J].
Apanovitch, DM ;
Slep, KC ;
Sigler, PB ;
Dohlman, HG .
BIOCHEMISTRY, 1998, 37 (14) :4815-4822
[3]   REGULATION OF POSTRECEPTOR SIGNALING IN THE PHEROMONE RESPONSE PATHWAY OF SACCHAROMYCES-CEREVISIAE [J].
BLINDER, D ;
JENNESS, DD .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (09) :3720-3726
[4]  
BRENNER S, 1974, GENETICS, V77, P71
[5]   Mutations in a C-elegans G(q)alpha gene disrupt movement, egg laying, and viability [J].
Brundage, L ;
Avery, L ;
Katz, A ;
Kim, UJ ;
Mendel, JE ;
Sternberg, PW ;
Simon, MI .
NEURON, 1996, 16 (05) :999-1009
[6]  
BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469
[7]   Mixed incontinence [J].
Chaliha, C ;
Khullar, V .
UROLOGY, 2004, 63 (3A) :51-57
[8]   Two RGS proteins that inhibit Gαo and Gαq signaling in C-elegans neurons require a Gβ5-like subunit for function [J].
Chase, DL ;
Patikoglou, GA ;
Koelle, MR .
CURRENT BIOLOGY, 2001, 11 (04) :222-231
[9]   Fluoxetine-resistant mutants in C-elegans define a novel family of transmembrane proteins [J].
Choy, RKM ;
Thomas, JH .
MOLECULAR CELL, 1999, 4 (02) :143-152
[10]   Mechanisms involved in new therapies for overactive bladder [J].
Cruz, F .
UROLOGY, 2004, 63 (3A) :65-73